SK Bioscience

And the vaccine work has not worked in infants.

So what we were doing is a prophylactic monoclonal antibody, which has since been licensed to SK Bio in Korea.

And what our goal was was to basically be a passive vaccination.

Like, here, we're going to give you a long half-life antibody that's going to protect you from infection.